Dorinem IV Infusion 500 mg/vial is a broad-spectrum antibiotic belonging to the class of carbapenems. It is used for the treatment of various bacterial infections by inhibiting bacterial cell wall synthesis. It is effective against a wide range of Gram-positive and Gram-negative bacteria, including some that are resistant to other antibiotics.
Dorinem IV Infusion 500 mg/vial is primarily used for the treatment of complicated intra-abdominal infections, complicated urinary tract infections, and complicated skin and soft tissue infections. It is also used in hospital settings for serious infections where other antibiotics might not be effective.
| Brand Name | Dorinem |
|---|---|
| Type | IV Infusion |
| Weight | 500 mg/vial |
| Generic | Doripenem |
| Manufacturer | ACI Limited |
| Available in | English বাংলা |
Dorinem IV Infusion 500 mg/vial works by inhibiting bacterial cell wall synthesis. It binds to penicillin-binding proteins (PBPs) in the bacterial cell wall, which prevents the cross-linking of peptidoglycan layers. This disruption leads to bacterial cell lysis and death.
Clinical improvement is typically observed within 48 to 72 hours of starting Dorinem IV Infusion 500 mg/vial, though it may vary depending on the severity and type of infection.
Dorinem IV Infusion 500 mg/vial is administered intravenously, so it does not undergo absorption through the gastrointestinal tract. Its bioavailability is therefore complete when given by IV administration.
Dorinem IV Infusion 500 mg/vial is primarily eliminated through the kidneys. It is excreted unchanged in the urine, with minimal amounts eliminated through the bile.
The usual dosage for Dorinem IV Infusion 500 mg/vial in adults is 500 mg administered intravenously every 8 hours. The duration of therapy depends on the type and severity of the infection but typically ranges from 5 to 14 days.
Dorinem IV Infusion 500 mg/vial is administered intravenously. It should be given over a period of 1 hour to avoid potential side effects. The dosage and duration should be adjusted based on the patient’s condition and response to treatment.
Common side effects include nausea, diarrhea, headache, rash, and phlebitis at the injection site. Serious side effects may include allergic reactions, seizures, and Clostridium difficile-associated diarrhea.
High doses or prolonged use of Dorinem IV Infusion 500 mg/vial may lead to toxicity, including neurological symptoms such as seizures. Monitoring kidney function and adjusting the dosage in cases of renal impairment is essential to prevent toxicity.
Precautions should be taken in patients with a history of seizures, renal impairment, or hypersensitivity to beta-lactam antibiotics. Dosage adjustments may be required for patients with renal issues.
Dorinem IV Infusion 500 mg/vial may interact with other medications, including probenecid, which can increase its levels in the blood and enhance its side effects. Caution is advised when used with other nephrotoxic drugs.
Special caution is needed in patients with renal disease as Dorinem IV Infusion 500 mg/vial is predominantly eliminated by the kidneys. It should be used with care in patients with a history of seizures or central nervous system disorders.
Dorinem IV Infusion 500 mg/vial may interact with certain drugs, including valproic acid, potentially reducing its levels and efficacy. Monitoring and dose adjustments may be necessary when used concurrently with such medications.
As Dorinem IV Infusion 500 mg/vial is administered intravenously, food interactions are not a concern. However, oral medications should be managed with care to avoid interactions that could affect Dorinem IV Infusion 500 mg/vial treatment.
Dorinem IV Infusion 500 mg/vial falls under Category B for pregnancy, indicating that it is not expected to be harmful to an unborn baby based on animal studies. However, its use should be considered only if the benefits outweigh the risks.
It is not known if Dorinem IV Infusion 500 mg/vial is excreted in human breast milk. Caution is advised when administering Dorinem IV Infusion 500 mg/vial to nursing mothers. The decision to use this drug should consider potential benefits and risks to the infant.
Acute overdose may lead to symptoms such as seizures and gastrointestinal disturbances. Treatment should include supportive measures and symptomatic management. Dialysis may help to remove excess Dorinem IV Infusion 500 mg/vial from the bloodstream.
Dorinem IV Infusion 500 mg/vial is contraindicated in patients with a known hypersensitivity to carbapenems, other beta-lactam antibiotics, or any component of the formulation.
Dorinem IV Infusion 500 mg/vial should be administered strictly according to the prescribed dosage and duration. Ensure proper hydration and monitor for any adverse effects during treatment.
Dorinem IV Infusion 500 mg/vial should be stored at 25°C (77°F), protected from light and moisture. Do not freeze. Once reconstituted, the solution should be used within the recommended time frame.
The volume of distribution of Dorinem IV Infusion 500 mg/vial is approximately 20-30 liters, indicating its extensive distribution in body tissues and fluids.
The elimination half-life of Dorinem IV Infusion 500 mg/vial is approximately 1 hour, which necessitates frequent dosing to maintain effective drug levels.
Dorinem IV Infusion 500 mg/vial clearance is primarily renal, with approximately 70-90% of the drug excreted unchanged in the urine. Renal function should be monitored to adjust dosing as necessary.
See in details version Dorinem IV Infusion 500 mg/vial also Dorinem IV Infusion 500 mg/vial in bangla